Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Matthias H. Busch et al.|The Lancet Rheumatology|2020Cited by 199
In vivo regulation of neutrophil apoptosis by C5a during sepsisRen-Feng Guo, Peter A. Ward|Journal of Leukocyte Biology|2006Cited by 77